GENMAB A/S's ticker is GMAB and the CUSIP is 372303206. A total of 201 filers reported holding GENMAB A/S in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,999,306 | +0.9% | 226,802 | -8.1% | 0.06% | -6.1% |
| Q3 2022 | $7,930,000 | +15.8% | 246,828 | +17.1% | 0.07% | 0.0% |
| Q2 2022 | $6,846,000 | +103.2% | 210,738 | +126.3% | 0.07% | +120.0% |
| Q1 2022 | $3,369,000 | -5.7% | 93,110 | +3.0% | 0.03% | -6.2% |
| Q4 2021 | $3,574,000 | -37.8% | 90,371 | -31.3% | 0.03% | -45.8% |
| Q3 2021 | $5,745,000 | +74.9% | 131,469 | +63.4% | 0.06% | +68.6% |
| Q2 2021 | $3,284,000 | -33.6% | 80,450 | -46.6% | 0.04% | -41.7% |
| Q1 2021 | $4,945,000 | +40.2% | 150,633 | +73.6% | 0.06% | +27.7% |
| Q4 2020 | $3,528,000 | +9.8% | 86,759 | -1.1% | 0.05% | -23.0% |
| Q3 2020 | $3,213,000 | +14.0% | 87,768 | +5.6% | 0.06% | +60.5% |
| Q2 2020 | $2,818,000 | +276.7% | 83,110 | +135.4% | 0.04% | -19.1% |
| Q1 2020 | $748,000 | -67.3% | 35,308 | -65.5% | 0.05% | -16.1% |
| Q4 2019 | $2,287,000 | -57.2% | 102,400 | -61.2% | 0.06% | -64.3% |
| Q3 2019 | $5,349,000 | – | 264,045 | – | 0.16% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 242,848 | $9,169,940 | 3.80% |
| Capricorn Fund Managers Ltd | 110,643 | $4,177,880 | 1.28% |
| Arlington Capital Management, Inc. | 35,591 | $1,343,916 | 1.26% |
| XY Capital Ltd | 76,884 | $2,903,140 | 1.13% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 88,000 | $3,322,880 | 0.93% |
| TORRAY INVESTMENT PARTNERS LLC | 110,807 | $4,184,072 | 0.75% |
| Hardman Johnston Global Advisors LLC | 585,139 | $22,094,849 | 0.72% |
| Yorktown Management & Research Co Inc | 16,600 | $626,816 | 0.68% |
| First Light Asset Management, LLC | 160,025 | $6,042,544 | 0.54% |
| MIRABELLA FINANCIAL SERVICES LLP | 28,260 | $2,505,855 | 0.38% |